We are a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. We designed our product candidates to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Our lead product candidate, PHX1149, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that we are developing as an oral, once-daily treatment for Type 2 diabetes. Our second product candidate, PHX1766, is a protease inhibitor currently in preclinical development for the treatment of hepatitis C virus, or HCV, infection.
|
